About Hill-Rom (NYSE:HRC)
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment. The company also offers patient monitoring and diagnostics products, such as blood pressure, physical assessment, vital signs monitoring, diagnostic cardiopulmonary, diabetic retinopathy screening, and thermometry products; and respiratory health products, including Vest, VitalCough, MetaNeb, and Monarch systems to assist patients in the mobilization of retained blockages. In addition, it provides surgical solutions products comprising surgical tables, lights, and pendants; positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries; platform-neutral positioning accessories; and operating room surgical safety and accessory products, such as scalpels and blades, light handle systems, skin markers, and other disposable products. The company sells and rents its products to acute and extended care facilities through direct sales force and distributors; and directly to patients in the home, as well as sells its products to primary care facilities through distributors. Further, it offers diagnostic cardiology devices, to serve the continuum of clinical care, from acute care to primary care, and clinical research organizations. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Chicago, Illinois.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
Trailing P/E Ratio23.67
Forward P/E Ratio19.70
Sales & Book Value
Annual Sales$2.74 billion
Price / Sales2.20
Cash Flow$7.1466 per share
Price / Cash12.76
Book Value$20.73 per share
Price / Book4.40
EPS (Most Recent Fiscal Year)$3.86
Net Income$133.60 million
Return on Equity20.18%
Return on Assets6.32%
Hill-Rom (NYSE:HRC) Frequently Asked Questions
What is Hill-Rom's stock symbol?
Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC."
How often does Hill-Rom pay dividends? What is the dividend yield for Hill-Rom?
Hill-Rom declared a quarterly dividend on Thursday, May 10th. Stockholders of record on Friday, June 22nd will be paid a dividend of $0.20 per share on Friday, June 29th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Thursday, June 21st. View Hill-Rom's Dividend History.
How were Hill-Rom's earnings last quarter?
Hill-Rom Holdings, Inc. (NYSE:HRC) announced its quarterly earnings data on Friday, April, 27th. The medical technology company reported $1.05 EPS for the quarter, beating the consensus estimate of $1.02 by $0.03. The medical technology company had revenue of $710.50 million for the quarter, compared to analysts' expectations of $707.54 million. Hill-Rom had a net margin of 6.85% and a return on equity of 20.18%. Hill-Rom's quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.88 earnings per share. View Hill-Rom's Earnings History.
When is Hill-Rom's next earnings date?
What guidance has Hill-Rom issued on next quarter's earnings?
Hill-Rom updated its FY18 earnings guidance on Friday, April, 27th. The company provided EPS guidance of $4.60-4.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.61. The company issued revenue guidance of $2.83-2.85 billion (+3-5%), compared to the consensus revenue estimate of $2.85 billion.Hill-Rom also updated its Q3 guidance to $1.12-1.14 EPS.
What price target have analysts set for HRC?
9 brokers have issued 12 month price objectives for Hill-Rom's shares. Their predictions range from $85.00 to $106.00. On average, they anticipate Hill-Rom's share price to reach $93.75 in the next year. View Analyst Ratings for Hill-Rom.
What are Wall Street analysts saying about Hill-Rom stock?
Here are some recent quotes from research analysts about Hill-Rom stock:
- 1. According to Zacks Investment Research, "Hill-Rom exited the fiscal second quarter on a strong note. The company saw a solid year-over-year increase in revenues on strong international growth. The upside was driven by double-digit growth in Canada and the Middle East, along with strength in Europe and Latin America. The company is also focusing on product innovation through research and development. In this regard, Hill-Rom recently announced the upgrading of its Welch Allyn Spot Vision Screener. Also, the company’s long-range financial objectives through 2020, looks promising. However, a decline in revenues at the company's Patient Support Systems segment is quite disappointing. Also, foreign exchange and a tough competitive landscape remain headwinds. Overall, Hill-Rom has outperformed its industry in three-month' time." (5/1/2018)
- 2. Needham & Company LLC analysts commented, "Consistent with its 1/9/18 preannouncement, HRC beat consensus F1Q18 revenue and EPS. Management reiterated its FY18 revenue guidance and raised its FY18 adjusted EPS guidance due to tax reform. Organic revenue growth slowed somewhat to 2% in F1Q18 from 3% in F4Q17. Margins increased modestly Y/ Y with gross margin up 20 bps and operating margin up 10 bps and tax reform added $0.06 to EPS. One surprise was that CEO John Greisch announced his intention to retire in F3Q18; the board has initiated a CEO search. We expect new products including the Centrella bed to drive accelerating revenue growth while cost reductions and portfolio management drive margin expansion. HRC shares remain at a discount to peers (2018E P/E of 18.5x vs. small/mid-cap value peers at 24.3x) and we reiterate our Buy rating." (1/26/2018)
Who are some of Hill-Rom's key competitors?
Some companies that are related to Hill-Rom include ABIOMED (ABMD), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), ICU Medical (ICUI), Insulet (PODD), Globus Medical (GMED), Penumbra (PEN), Haemonetics (HAE), Cantel Medical (CMD), NuVasive (NUVA), Novocure (NVCR), Merit Medical Systems (MMSI), Nevro (NVRO) and Irhythm Technologies (IRTC).
Who are Hill-Rom's key executives?
Hill-Rom's management team includes the folowing people:
- Mr. William Gerard Dempsey, Exec. Chairman (Age 67)
- Mr. John J. Greisch, Pres, CEO & Director (Age 63)
- Mr. Steven J. Strobel, Sr. VP & CFO (Age 60)
- Ms. Deborah M. Rasin, Sr. VP, Chief Legal Officer & Sec. (Age 51)
- Mr. Alton E. Shader, Sr. VP, Pres of Welch Allyn & Front Line Care (Age 45)
Has Hill-Rom been receiving favorable news coverage?
Media stories about HRC stock have trended positive this week, Accern reports. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hill-Rom earned a daily sentiment score of 0.34 on Accern's scale. They also gave media coverage about the medical technology company an impact score of 43.35 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Hill-Rom's major shareholders?
Hill-Rom's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.32%), Fisher Asset Management LLC (2.14%), Lord Abbett & CO. LLC (1.76%), Neuberger Berman Group LLC (1.65%), Wells Fargo & Company MN (1.64%) and Ceredex Value Advisors LLC (1.60%). Company insiders that own Hill-Rom stock include Alton Shader, Andreas G Frank, Andrew Macritchie, Carlyn D Solomon, Deborah Rasin, John J Greisch, Mary Garrett and Paul Sherwood Johnson. View Institutional Ownership Trends for Hill-Rom.
Which institutional investors are selling Hill-Rom stock?
HRC stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Millennium Management LLC, Franklin Resources Inc., Victory Capital Management Inc., Rothschild Asset Management Inc., Allianz Asset Management GmbH, Allianz Asset Management GmbH and Fisher Asset Management LLC. Company insiders that have sold Hill-Rom company stock in the last year include Alton Shader, Andreas G Frank, Deborah Rasin, John J Greisch and Paul Sherwood Johnson. View Insider Buying and Selling for Hill-Rom.
Which institutional investors are buying Hill-Rom stock?
HRC stock was acquired by a variety of institutional investors in the last quarter, including Ceredex Value Advisors LLC, BlackRock Inc., Amundi Pioneer Asset Management Inc., Lord Abbett & CO. LLC, Prudential Financial Inc., Systematic Financial Management LP, Thrivent Financial for Lutherans and Mackay Shields LLC. Company insiders that have bought Hill-Rom stock in the last two years include Andrew Macritchie and Mary Garrett. View Insider Buying and Selling for Hill-Rom.
How do I buy shares of Hill-Rom?
Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hill-Rom's stock price today?
One share of HRC stock can currently be purchased for approximately $91.19.
How big of a company is Hill-Rom?
Hill-Rom has a market capitalization of $6.04 billion and generates $2.74 billion in revenue each year. The medical technology company earns $133.60 million in net income (profit) each year or $3.86 on an earnings per share basis. Hill-Rom employs 10,000 workers across the globe.
How can I contact Hill-Rom?
Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at 312-819-7200 or via email at [email protected]
MarketBeat Community Rating for Hill-Rom (HRC)MarketBeat's community ratings are surveys of what our community members think about Hill-Rom and other stocks. Vote "Outperform" if you believe HRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRC will underperform the S&P 500 over the long term. You may vote once every thirty days.